Searched for
DRUG MULTINATIONALS
Pharma in her DNA, Wockhardt scion ready for deep dive in the USZahabiya Khorakiwala is leading Wockhardt's US business and the launch of its new antibiotic, Zaynich. This drug targets resistant bacteria...- Wockhardt shares jump 8%, extend rally after CDSCO nod for Zaynich antibioticWockhardt shares surged after the company received CDSCO approval for its breakthrough antibiotic Zaynich in India. Strong Phase 3 trial re...
- From diapers to drugs: How India's global corporate hubs are putting AI to workHeads of several Global Capability Centres (GCCs) told Reuters they are deploying AI across a host of functions - from marketing and conten...
- Wockhardt gets CDSCO nod for Zaynich antibioticWockhardt Ltd has secured approval from the CDSCO for its new antibiotic, Zaynich. This drug is developed in India and will be used to trea...
- Global firms bring more work in-house at India hubs on AI boostThe shift reflects a structural change in how multinationals use their India operations, moving beyond cost-focused support roles to centre...
- Global firms bring more work in-house at India hubs on AI boostGlobal firms are bringing more work in-house at their India centres. Artificial intelligence is boosting productivity. This reduces relianc...
- Global firms rethink GCC hiring in India as AI shifts skill demandGlobal firms in India are hiring cautiously. Artificial intelligence is changing job roles, making it harder to find talent with advanced t...
- From oncology to obesity, Pfizer bets big on India for its next growth wavePfizer is prioritizing India for future growth. The company plans to launch new medicines here soon after their global release. Pfizer aims...
- Hospitals warn Central Government Health Scheme reimbursement cap may hurt cancer treatmentA major private hospital group warns of a crisis for advanced cancer patients under the Central Government Health Scheme. A reimbursement c...
- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- The alchemist of Bengaluru: Kiran Mazumdar-Shaw began from a garageKiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who b...
- Scientists have discovered that cocaine-powered super salmon live longer and swim faster than normal salmonScientists found Atlantic salmon exposed to cocaine swam further and lived longer. This study highlights how drugs in waterways change aqua...
- Funding for innovations key for India to remain vaccine leader: Cyrus PoonawallaSpeaking to ET after receiving the Lifetime Achievement Award for 2025 as part of the ET Awards for Corporate Excellence, Cyrus Poonawalla,...
- Demand for senior technology leaders in India is bucking a slowdown in broader tech hiringAs per experts, many MNCs are considering shifting global tech positions to India, mostly to their GCCs. Ratna Gupta, senior partner, ABC C...
- With sights on huge gains, Biocon to scale up AI focusBiopharma major Biocon is significantly scaling up its adoption of artificial intelligence across its operations, from R&D to manufacturing...
- Aurobindo Pharma approves Rs 800 crore share buyback. Check record date, other key detailsAurobindo Pharma is launching its first share buyback in two years, offering to repurchase over 54 lakh shares at Rs 1,475 each. This tende...
- Fear of duty hike raising drug prices unfoundedThe withdrawal of customs duty exemption on 76 drugs has led to a hue and cry with many doctors claiming this would make these life-saving ...
- Cipla teams up with Gilead Lifesciences to make Hepatitis C drug under voluntary licenceOn the face of it, there is nothing wrong with this kind of a deal. Pharma companies ink many such pacts on a regular basis.
- Tuberculosis drug shortage calls for stringent penaltyThis horrific situation has come about because of dither and delay in the government machinery that procures TB drugs.
- Novartis lost patent case on technical groundNovartis lost its case on technical grounds. It failed to establish that the drug’s new form was sufficiently patentable.
Load More
